Latest News & Features
Americas
US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations. 4 February 2020
Americas
Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences. 4 February 2020
Biotechnology
The UK Intellectual Property Office and the Chartered Institute of Patent Attorneys have worked together to ensure changes are made to “misleading” advice issued by the EU’s Community Plant Variety Office. 3 February 2020
Big Pharma
The Court of Justice of the European Union has ruled that pharmaceutical pay-for-delay agreements may violate the Treaty on the Functioning of the European Union, in comments passed down on January 30, 2020. 31 January 2020
Americas
Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya. 30 January 2020
Americas
The US Court of Appeals for the Federal Circuit has thrown out Sanofi’s request to apply the recent Arthrex ruling on the constitutionality of the Patent Trial and Appeal Board to more cases. 30 January 2020
Americas
The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health. 30 January 2020
Big Pharma
DNA testing developer Natera is suing ArcherDX, a molecular technology company, for allegedly infringing a patent related to multiplex polymerase chain reaction technology. 29 January 2020
Americas
The US Federal Trade Commission and New York’s attorney general have sued incarcerated ‘pharma bro’ Martin Shkreli for allegedly monopolising the market for life-saving drug Daraprim. 28 January 2020
Big Pharma
Biopharmaceutical company AbbVie’s pending purchase of pharmaceutical company Allergan has moved a step closer, following the latter’s agreement to divest treatments brazikumab and Zenpep, in a development meant to satisfy antitrust regulations in the US. 28 January 2020